.jpg?format=webp&quality=80&width=3840)
Lupin Limited has secured tentative approval from the US FDA for its generic Rivaroxaban Tablets USP, an anticoagulant for stroke prevention, deep vein thrombosis, and pulmonary embolism treatment. The approval covers doses of 2.5 mg, 10 mg, 15 mg, and 20 mg, providing an alternative to Xarelto. The generic will be produced at Lupin's Pithampur facility in India, expanding access to this crucial medication for various cardiovascular conditions.
Like
Save
Share